The main findings of this clinical study are that in patients with unstable angina, trimetazidine treatment prevented the increase in CK-MB, cTnI, and vWF and the decrease in NO induced by PCI but did not significantly affect the levels of h-FABP. The gene discussed is FABP3; the disease is angina pectoris.